New Issue: Science’s Impossible Questions. Read Now

Boozy Memory Blocking Reduces Risk of Relapse among Alcohol Abusers

A molecule associated with learning and memory consolidation could be key to treating alcoholism

Join Our Community of Science Lovers!

Wiping out drinking-associated memories could help those with alcohol problems to stay sober, suggests a study in rats.

As with other forms of addiction, environmental cues linked to drinking — such as the smell of beer — can trigger the urge to consume alcohol and increase the risk of a relapse into abuse. Over time, these learned associations can be maddeningly difficult to break.

Scientists have now identified a potential molecular target in the brains of rats that could one day lead to treatments to help people stay dry. Dorit Ron, a neuroscientist at the University of California, San Francisco (UCSF), and her team show that strategically blocking the mTORC1 signaling pathway reduces alcoholic relapse by disrupting memories linked to past drinking. This pathway controls the production of several proteins associated with learning and memory.


On supporting science journalism

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.


A memory is thought to become vulnerable when it is retrieved, like a folder checked out from a library archive. Pages can be shuffled or lost before the folder is returned to long-term storage. A number of studies have suggested that disrupting the mTORC1 pathway during this time window can destabilize the process of memory restoration and can potentially help treat post-traumatic stress disorder as well as drug addiction.

In the latest study, published today in Nature Neuroscience, rats became problem drinkers after spending seven weeks exposed to a choice of water or a mixture of water and 20% alcohol. Ron says that the concoction probably tastes terrible to the rodents, but the animals eventually drink it in large quantities.

“It’s pretty amazing. You don’t do anything,” she says. “Over time, you can see they develop a strong preference for alcohol.” When the animals binged on alcohol, they reached concentrations of about 80 milligrams per 100 milliliters of blood — the legal driving limit in both the United Kingdom and the United States.

The researchers took alcohol away from the animals for 10 days and then gave each of them a tiny drop — just enough for the taste and odor to reawaken alcohol-related memories. Immediately afterwards, some rats received a drug called rapamycin, which inhibits mTORC1 activity.

All the rats had been trained to press a lever to receive alcohol, but those that received rapamycin after memory reactivation showed significantly less inclination to do so over a two-week period.

Doctoring memories
“We don’t know what the specific memory is that we’re messing with, but we know the cue that’s triggering it,” says co-author Patricia Janak, a UCSF neuroscientist. Ron says that the memory trace disrupted by rapamycin is probably that which links the smell and taste to the pleasurable effects of alcohol consumption.

“It’s really excellent,” says Charles O’Brien, director of the Center for Studies of Addiction at the University of Pennsylvania in Philadelphia, referring to the study. “Fundamentally, addiction is a memory, and [the authors] are going straight at what is actually going on in the brain.”

Rapamycin does not seem to affect memory formation, but instead disrupts the reconsolidation of existing memories into long-term storage after they have been reactivated. Preliminary tests suggest that the drug’s effects can be quite specific, and do not affect the animals’ consumption of other desirable substances such as sugar-water.

Although Ron says her group does not plan to pursue studies in humans, she says that research by others may turn rapamycin or a related compound into an effective treatment for alcohol abuse. The US Food and Drug Administration has already approved rapamycin as an immunosuppressant for organ-transplant recipients.

“I would be eager to try this in my patients as soon as it can be determined that it’s safe,” says O’Brien.

This article is reproduced with permission from the magazine Nature. The article was first published on June 23, 2013.

Helen Shen is a science writer based in Sunnyvale, Calif. She has contributed to Nature, Science and the Boston Globe.

More by Helen Shen

First published in 1869, Nature is the world's leading multidisciplinary science journal. Nature publishes the finest peer-reviewed research that drives ground-breaking discovery, and is read by thought-leaders and decision-makers around the world.

More by Nature magazine

Subscribe to Support Independent Journalism

Great science journalism requires human expertise, time, effort and creativity. And it costs money. That’s why I and the journalists here at Scientific American hope you’ll join our community.

When you subscribe, you are supporting staff and freelance journalists who are passionate about telling science stories that are true, important and compelling. Our editors and reporters are often experts in their fields, which means they understand the nuances of big discoveries and can untangle the breakthroughs from the hype. With a subscription, you are also supporting rigorous fact-checking to ensure the words we publish are precise and accurate. And you’re supporting original illustrations, graphics and photos that bring you closer to an advanced laboratory, an ice sheet in Antarctica or a space mission in orbit. You’re helping us craft other types of high-quality journalism as well: Our newsletters are carefully written, edited and curated by staffers you have or will come to know and love. Our Science Quickly podcast is based on original reporting, collaboration with editors and scientists and exacting production.

Subscriptions keep this engine running so we can continue to deliver thoughtful, rigorous and independent science journalism to you. In an era of viral misinformation, this work is crucial. If you value what we do, I hope you’ll consider joining us as a subscriber

Thank you,

Jeanna Bryner, Editor in Chief, Scientific American

Subscribe